Cabaletta Bio (CABA) Cash & Equivalents (2018 - 2025)

Cabaletta Bio's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $83.0 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 49.39% year-over-year to $83.0 million; the TTM figure through Dec 2025 stood at $83.0 million (down 49.39% YoY), while the FY2025 annual figure was $83.0 million, down 49.39% from the prior year.
• Cash & Equivalents was $83.0 million for Q4 2025 at Cabaletta Bio, up from $60.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $223.8 million in Q1 2024 to a low of $60.2 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $132.1 million across 5 years, with a median of $120.7 million in 2021.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 138.53% in 2024, then tumbled 67.1% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $122.2 million in 2021, then slumped by 33.23% to $81.6 million in 2022, then jumped by 136.79% to $193.2 million in 2023, then fell by 15.15% to $164.0 million in 2024, then tumbled by 49.39% to $83.0 million in 2025.
• The last three Cash & Equivalents figures came in at $83.0 million (Q4 2025), $60.2 million (Q3 2025), and $145.6 million (Q2 2025), per Business Quant data.